After Hours Summary: DRWI +16.1%, ZUMZ +10.5%, LL -19.1%, PBPB -16.4%, HELI -7.3%, TSCO -5.6% following earnings/guidance
After Hours Gainers: Companies trading higher in after hours in reaction to earnings: DRWI +16.1%, ZUMZ +10.5%
Companies trading higher in after hours in reaction to news: CWH +6.9% (co sold its 22 mln shares of Select Income REIT (SIR) for $31.51 per share; total consideration is ~$705 mln), UAL +6.4% (reported June 2014 consolidated traffic (RPM) was flat y/y, consolidated capacity (ASM) increased 0.8% vs June 2013, consolidated load factor decreased 0.6 points compared to June 2013), SSE +4.2% (Carl Icahn disclosed 9.98% stake in 13D filing), APP +3.6% (disclosed an agreement with Standard General Group; agreement relates to, among other things, the composition of the Company's Board of Directors, the provision by SG of financial support to the Company in an aggregate amount up to $25 million, and the creation of a special committee of the Board to oversee the continuing investigation into alleged misconduct by Dov Charney), ZNGA +1.7% (appointed Google VP Regina Dugan to Board of Directors), REGN +0.8% (co and Sanofi (SNY) announced positive results from Phase 2b study of dupilumab in patients with moderate-to-severe atopic dermatitis)
After Hours Losers:
Companies trading lower in after hours in reaction to earnings: LL -19.1%, PBPB -16.4%, HELI -7.3%, TSCO -5.6%, WDFC -5.3%, HELE -4.9%, BGC -0.1%
Companies trading lower in after hours in reaction to news: MEMP -4.3% (announced public offering of 8.6 mln common units), AXLL -3.8% (announced that its PHH vinyl chloride monomer manufacturing facility in Lake Charles, Louisiana, has been repaired and the facility has returned to full operating rates; sees Q2 adjusted EBITDA of $125-130 mln), KOS -3.7% (announced that funds affiliated with The Blackstone Group L.P. and Warburg Pincus LLC have agreed to sell an aggregate of 17 mln of Kosmos's common shares in a registered underwritten public offering), RGDO -2.2% (announced clinical hold of REGULATE-PCI trial following voluntary halt of trial by Regado)